Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

CV Therapeutics  (Stock symbol: CVTX ) Acquired by Gilead Sciences (2009 $ 1,400,000,000 )

3172 Porter Drive
Palo Alto, CA 94304
USA
650-384-8500
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Joseph M Davie (Biogen SVP Research);  Santo J Costa (Quintiles President);  Thomas L Gutshall (Cepheid) Kenneth B Lee (A.M. Pappas & Associates) Thomas E Shenk (Princeton University Professor)
Former outside board: Ian Angell (London School of Economics);  Peter Barton Hutt (Covington & Burling);  R Scott Green (Abgenix);  John Groom (Elan President/COO);  Barbara McNeil (Harvard Medical School Department Chairman);  Costa Sevastopoulos (independent consultant)
Company

Business description: CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company’s European subsidiary based in the United Kingdom. CV Therapeutics’ approved products in the United States include Ranexa® (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan® (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa® (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.
Partners include: Genta
Capital

Capital raised: 54.0M
Ownership: Acquired by Gilead Sciences (2009 $ 1,400,000,000 )
Stock Symbol: CVTX

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2009
Sector: Biotech
Year Founded: 1990
Headcount: 501-600 as of Mar 2009
Capital Raised: 54.0M
Ownership: Acquired by Gilead Sciences (2009 $ 1,400,000,000 )
Stock Symbol: CVTX